March 28th 2024
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
New Bladder Cancer Treatments Increase Life Expectancy in Advanced Bladder Cancer
November 1st 2001ANAHEIM, California-A phase III Intergroup trial has provided strong evidence that neoadjuvant MVAC-methotrexate, vinblastine, doxorubicin (Adriamycin), cisplatin (Platinol)-provides a survival benefit in patients with locally advanced bladder cancer, David Crawford, MD, said at the American Urological Association (AUA) annual meeting (abstract 1069).
Molecular Markers for Diagnosis, Staging, and Prognosis of Bladder Cancer
November 1st 2001Conventional histopathologic evaluation of bladder cancer, encompassing tumor grade and stage, is inadequate to accurately predict the behavior of most bladder tumors. Intense research efforts are under way to identify and
Molecular Markers for Diagnosis, Staging, and Prognosis of Bladder Cancer
November 1st 2001Conventional histopathologic evaluation of bladder cancer, encompassing tumor grade and stage, is inadequate to accurately predict the behavior of most bladder tumors. Intense research efforts are under way to identify and
Molecular Markers for Diagnosis, Staging, and Prognosis of Bladder Cancer
November 1st 2001Conventional histopathologic evaluation of bladder cancer, encompassing tumor grade and stage, is inadequate to accurately predict the behavior of most bladder tumors. Intense research efforts are under way to identify and
Optimizing Mitomycin Use Ups Bladder Cancer Outcome
October 1st 2001ANAHEIM, California-In patients with superficial bladder cancer, it is possible to optimize treatment with mitomycin (Mutamycin) by enhancing the drug concentration in urine, according to the results of a multicenter study presented at the American Urological Association annual meeting (abstract 776).
NSAIDs May Protect Against Development of Prostate Cancer
October 1st 2001ANAHEIM, California-Prostate cancer can now be added to the list of malignancies for which nonsteroidal anti-inflammatory agents (NSAIDs) may have a protective effect, according to experimental and clinical research presented at the American Urological Association annual meeting.
Southwest Oncology Group Studies Vitamin E, Selenium to Prevent Prostate Cancer
September 1st 2001BETHESDA, Maryland-Researchers have begun accruing 32,400 men for a long-term prostate cancer study that will test whether selenium and/or vitamin E can prevent the disease. The Southwest Oncology Group (SWOG) will coordinate the Selenium and Vitamin E Cancer Trial (SELECT) at more than 400 sites in the United States, Canada, and Puerto Rico. Participants will be followed for up to 12 years.
Three-Dimensional Conformal Radiation Therapy Reduces Rectal Damage in Prostate Cancer Treatment
August 2nd 2001ST. LOUIS-Three-dimensional (3D) conformal radiation therapy is being widely used for treatment of prostate cancer and has been successful at reducing rectal toxicities. "Conformal radiotherapy has allowed dose escalation with acceptable or even reduced rates of severe morbidity," Jeff M. Michalski, MD, reported. He added, however, that "we have to start paying attention to the low-grade morbidity. Grade 1 and grade 2 toxicity may predict development of severe late complications." Dr. Michalski is assistant professor of radiology, Mallinckrodt Institute of Radiology, Washington University, St. Louis.
Intrarectal Amifostine Prevents Late Rectal Complications of Radiotherapy for Prostate Cancer
August 2nd 2001DETROIT-Intrarectal topical application of amifostine (Ethyol), given as a "mini-enema," is extremely tolerable, produces no systemic toxicity, and may be an alternative to systemic administration for preventing rectal damage in patients undergoing radiotherapy for prostate cancer. Results of a phase I study were reported by Edgar Ben-Josef, MD. He is associate professor in the Department of Radiation Oncology at Wayne State University’s Karmanos Cancer Institute in Detroit.
Atrasentan May Delay Advanced Prostate Cancer Progression
August 1st 2001SAN FRANCISCO-Atrasentan (ABT-627), an investigational endothelin-A receptor antagonist made by Abbott Laboratories, appears to delay clinical progression, PSA progression, and bone progression in hormone-refractory prostate cancer patients, according to phase II clinical trials presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Clodronate May Slow Bone Metastasis in Prostate Cancer
July 1st 2001SAN FRANCISCO-Oral sodium clodronate appears to have delayed progression of bone metastasis from prostate cancer in a randomized clinical trial, although the results did not reach statistical significance. British investigator David Dearnaley, MD, presented the preliminary results on behalf of the Medical Research Council (MRC) Clinical Trials Unit at the 37th Annual Meeting of the American Society for Clinical Oncology (ASCO) in San Francisco.
Zoledronic Acid Active Against Bone Metastasis in Prostate Cancer
July 1st 2001ANAHEIM, California-In a study of advanced prostate cancer patients, use of the investigational bisphosphonate zoledronic acid (Zometa) led to significantly fewer skeletal-related events associated with bone metastases (including radiation therapy for pain relief) than did placebo, according to data presented at the Society of Urologic Oncology meeting, held in conjunction with the 96th Annual Meeting of the American Urological Association.
High TIMP-1 Levels May Promote Prostate Cancer Growth
June 1st 2001SAN FRANCISCO-High levels of a protein that normally prevents tumor growth may actually encourage angiogenesis and the spread of prostate cancer, according to a poster presented at the 40th Annual Meeting of the American Society for Cell Biology.
Resolving Prostate Cancer Controversies Will Take Time: Walsh
June 1st 2001BETHESDA, Md-Rapid advances in managing prostate cancer over the last decade have created dilemmas for clinicians as they attempt to determine which treatment is best for each patient, said Patrick Walsh, MD, director, Department of Urology, Johns Hopkins University School of Medicine. Such dilemmas will not be resolved fast enough through randomized trials, he said.
Recent Developments in Chemotherapy for Bladder Cancer
June 1st 2001Drs. Vaughn and Malkowicz have provided us with a succinct, thorough, evidence-based overview of the current role of chemotherapy in advanced bladder cancer. Their discussion highlights the veritable explosion of new chemotherapy agents
Thalidomide Antiangiogenesis Explored in Prostate Cancer Studies
June 1st 2001BETHESDA, Md-Thalidomide (Thalomid) appears to inhibit angiogenesis (the recruitment of new blood vessels by the tumor). Clinically, thalidomide has been shown to lower PSA levels in some patients with androgen-independent prostate cancer. Using an LNCaP in vitro model, thalidomide has been shown to slightly increase the amount of PSA per cell number. "Some drugs appear to upregulate the expression of PSA and some downregulate it," William Dahut, MD, of the National Cancer Institute, said at an NCI conference on urologic oncology. This is clearly the case for carboxyamidotriazole (CAI) and TNP-470, both angiogenesis inhibitors, he said. CAI has been shown to downregulate PSA, whereas TNP-740 upregulated it.